CA2071898A1 - Inhibition de la croissance cellulaire au moyen de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et d'autres glycanes - Google Patents

Inhibition de la croissance cellulaire au moyen de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et d'autres glycanes

Info

Publication number
CA2071898A1
CA2071898A1 CA002071898A CA2071898A CA2071898A1 CA 2071898 A1 CA2071898 A1 CA 2071898A1 CA 002071898 A CA002071898 A CA 002071898A CA 2071898 A CA2071898 A CA 2071898A CA 2071898 A1 CA2071898 A1 CA 2071898A1
Authority
CA
Canada
Prior art keywords
sulfate
patient
effective amount
glial cell
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002071898A
Other languages
English (en)
Inventor
Diane M. Snow
Jerry Silver
Adrian Harel
Dikla Roufa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Gliatech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2071898A1 publication Critical patent/CA2071898A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002071898A 1989-10-27 1990-10-26 Inhibition de la croissance cellulaire au moyen de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et d'autres glycanes Abandoned CA2071898A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42837489A 1989-10-27 1989-10-27
US428,374 1989-10-27

Publications (1)

Publication Number Publication Date
CA2071898A1 true CA2071898A1 (fr) 1991-04-28

Family

ID=23698624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002071898A Abandoned CA2071898A1 (fr) 1989-10-27 1990-10-26 Inhibition de la croissance cellulaire au moyen de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et d'autres glycanes

Country Status (4)

Country Link
EP (1) EP0493533A4 (fr)
AU (1) AU6872691A (fr)
CA (1) CA2071898A1 (fr)
WO (1) WO1991006303A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US9956273B2 (en) 2002-05-04 2018-05-01 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US9987340B2 (en) 2006-10-10 2018-06-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US10323240B2 (en) 2005-09-26 2019-06-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US11141467B2 (en) 2003-05-16 2021-10-12 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US7008783B1 (en) 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US6140071A (en) * 1994-01-27 2000-10-31 Somatogen, Inc. Proteins with mutations to decrease N-terminal methylation
JP4429386B2 (ja) * 1994-12-01 2010-03-10 生化学工業株式会社 ケラタン硫酸オリゴ糖画分及びそれを含む薬剤
EP0747470A1 (fr) 1995-06-08 1996-12-11 The Procter & Gamble Company Compositions de nettoyage contenant du kératanase
EP0747469A1 (fr) * 1995-06-08 1996-12-11 The Procter & Gamble Company Compositions de nettoyage contenant du chondroitinase
FR2787329B1 (fr) * 1998-12-17 2001-02-09 Aventis Pharma Sa Nouvelle application therapeutique des heparines de bas poids moleculaire
AU6557299A (en) 1999-01-07 2000-07-13 Seikagaku Corporation Method for producing oligosaccharide, and novel oligosaccharide and pharaceutical composition containing the same
DE60008319T2 (de) 1999-07-21 2004-12-09 Seikagaku Corp. IL-12 Produktionsinhibitor
WO2002060471A2 (fr) * 2001-01-30 2002-08-08 Ich Productions Limited Ligands des proteines tyrosine phosphatases de type recepteur
MXPA04001334A (es) 2001-08-13 2004-05-05 Univ Florida Materiales y metodos para promover la reparacion de tejido nervioso.
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
US7511026B2 (en) * 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
ES2616749T3 (es) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
WO2005112986A2 (fr) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Procedes de purification de la chondroitinase et formulations stables de cette derniere
WO2006111348A1 (fr) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Utilisation d'heparine ou de derives de l'heparine pour la modulation du recepteur nogo controlant la croissance des neurites
US20110059508A1 (en) 2007-06-29 2011-03-10 National University Corporation Nagoya University Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
EP2307440A4 (fr) * 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc Inhibiteurs d'héparane sulfate
US20120295890A1 (en) * 2009-12-31 2012-11-22 Zacharon Pharmaceutical, Inc. Glycosaminoglycan inhibitors
EP3389674A4 (fr) * 2015-12-18 2019-09-11 Tega Therapeutics, Inc. Compositions de glycosaminoglycane cellulaire et leurs procédés de préparation et d'utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5299207A (en) * 1976-02-16 1977-08-19 Kaken Pharmaceut Co Ltd Remedy for cattle diarrhea
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
SE8304836D0 (sv) * 1983-09-09 1983-09-09 Pharmacia Ab Sett att bestemma forendringar i ledbrosk
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
US4808570A (en) * 1984-02-24 1989-02-28 University Of California Compositions and method for improving wound healing
US4710493A (en) * 1984-08-14 1987-12-01 Albert Landsberger Therapeutic agent for the use in cancer treatment
DE3441835A1 (de) * 1984-11-15 1986-05-22 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Blutstillungsmittel
IT1208509B (it) * 1985-03-13 1989-07-10 Mediolanum Farmaceutici Srl Processo per la produzione di eparan solfato e dermatan solfato naturali sostanzialmente puri eloro impiego farmaceutico.
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US4696816A (en) * 1985-11-07 1987-09-29 Brown Mark D Method for treating intervertebral disc displacement with enzymes
US4956348A (en) * 1986-02-19 1990-09-11 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with cyclic nucleotides
US4760131A (en) * 1986-04-23 1988-07-26 Collagen Corporation Wound-healing composition
SE456245B (sv) * 1986-07-09 1988-09-19 Pharmacia Ab Enzympreparation innehallande krillhyaluronidas
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US9956273B2 (en) 2002-05-04 2018-05-01 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8084441B2 (en) 2003-02-19 2011-12-27 Stellar Pharmaceuticals, Inc. Cystitis treatment with high dose chondroitin sulfate
US8334276B2 (en) 2003-02-19 2012-12-18 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8778908B2 (en) 2003-02-19 2014-07-15 Stellar International Inc. Cystitis treatment with high dose chondroitin sulfate
US11141467B2 (en) 2003-05-16 2021-10-12 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
US10323240B2 (en) 2005-09-26 2019-06-18 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US9987340B2 (en) 2006-10-10 2018-06-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants

Also Published As

Publication number Publication date
EP0493533A4 (en) 1992-10-28
AU6872691A (en) 1991-05-31
WO1991006303A1 (fr) 1991-05-16
EP0493533A1 (fr) 1992-07-08

Similar Documents

Publication Publication Date Title
CA2071898A1 (fr) Inhibition de la croissance cellulaire au moyen de sulfate de keratane, de sulfate de chondroitine, de sulfate de dermatane et d'autres glycanes
Zuo et al. Chondroitin sulfate proteoglycan with neurite‐inhibiting activity is up‐regulated following peripheral nerve injury
Landolt et al. Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth
Massoulie et al. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates
Bode-Lesniewska et al. Distribution of the large aggregating proteoglycan versican in adult human tissues.
Canning et al. A potent inhibitor of neurite outgrowth that predominates in the extracellular matrix of reactive astrocytes
US6960559B1 (en) Neurite growth regulatory factors
Perris et al. Spatial and temporal changes in the distribution of proteoglycans during avian neural crest development
Martini et al. The L2/HNK‐1 carbohydrate epitope is involved in the preferential outgrowth of motor neurons on ventral roots and motor nerves
Bovolental et al. Neurite outgrowth inhibitor of gliotic brain tissue. Mode of action and cellular localization, studied with specific monoclonal antibodies
US6025333A (en) Treatment of CNS tumors with metalloprotease inhibitors
Lemons et al. Intact aggrecan and chondroitin sulfate-depleted aggrecan core glycoprotein inhibit axon growth in the adult rat spinal cord
Nieto-Sampedro Neurite outgrowth inhibitors in gliotic tissue
US5684133A (en) Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions
Ng et al. Human central nervous system myelin inhibits neurite outgrowth
NO873504L (no) Fremgangsmaate for behandling av angina og myokardialinfarkter med omentallipider.
Hanafusa et al. In vitro and in vivo reversal of thyroid epithelial polarity: its relevance for autoimmune thyroid disease.
US7858578B2 (en) Methods of inducing neuronal growth by a Fucose-α(1-2) galactose (fuc-α(1-2) gal) moiety and a lectin
JP2001521008A (ja) 哺乳類の中枢神経系ミエリンを一過的に変えて神経再生を促進する免疫組成物及びその使用方法
Fukuzawa et al. Evidence that MIF plays a role in the development of pigmentation patterns in the frog
Sorrell et al. Monoclonal antibodies specific for keratan sulfate detect epithelial-associated carbohydrates
US20030032621A1 (en) Means for regulating hematopoietic differentiation
CN111447950B (zh) 活性调节剂
WO1997044059A2 (fr) Collagene de type ii de cartilage utilise en tant que facteur angiogenique
WO2002038168A2 (fr) Utilisation de proteines produites pendant la grossesse, fixant la selectine, de liposomes, de fragments de mucine natifs et de composes mimetiques pour traiter et prevenir des maladies infectieuses, pour empecher la metastatisation et pour prevenir des maladies tumorales

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 19991026